Business
Marina Biotech Announces a License Agreement to SMARTICLES
Marina Biotech Announces a License Agreement to SMARTICLES.
About this update from Adhera Therapeutics Inc.
[{"type":"text","content":"\n \n \n Marina Biotech Announces a License Agreement to SMARTICLES\n \n \nMarina Biotech Announces a License Agreement to SMARTICLES\n \n CITY OF INDUSTRY, CA--(Marketwired - Feb 7, 2017) - Marina Biotech, Inc. (OTCQB: MRNA) a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer, today announced that they have entered into a license agreement regarding the Company's SMARTICLES platform for the delivery of nanoparticles including small molecules, peptides, proteins and biologics. This represents the first time that the Company's SMARTICLES technologies have been licensed in connection with nanoparticles delivering small molecules, peptides, proteins and biologics. Under terms of the agreement, Marina could receive up to $90MM in success based milestones. Further details of the agreement were not disclosed.\n \"With the execution of this license agreement, the company extends its runway and enters into new areas of medicine,\" stated Joseph W. Ramelli, CEO of Marina Biotech. \"We are now beginning to see our delivery technologies used with various types of molecules and entities. We hope our delivery technologies continue to provide new therapeutic opportunities to the patient community.\"\n About Marina Biotech, Inc.\n Marina Biotech is a biotechnology company focused on the development and commercialization of innovative therapeutics for disease intersections of arthritis, hypertension, and cancer. Our pipeline includes combination therapies of oligonucleotide-based therapeutics and small molecules. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome). By its merger with IthenaPharma, Marina Biotech recently acquired IT-102/IT-103- next generation celecoxib- which will be developed together with CEQ508 as a therapeutic enhancer for therapies against FAP and CRC. IT-102/IT-103 are also being developed for the treatment of combined arthritis/ hypertension and treatment of pain requiring high dose of celecoxib. Additional information about Marina Biotech is available at http://www.marinabio.com.\n Marina Biotech Forward-Looking Statements\n Statements made in this news release may be forward-looking statements within the meaning of Federal Securit...